| Issue Date | Title | Author(s) |
| Oct-2021 | Efficacy and safety of induction therapy with IAd versus IRd regimen in fragile elderly patients with newly diagnosed multiple myeloma: results of a prospective multicenter clinical trail | Bao, Li; Lu, Minqiu; Liu, Peng; Zhuang, Junling; Zhang, Mei; Xia, Zhongjun; Li, Zhenling; Jing, Hongmei; Wu, Yin; Chen, Wen Ming; Zhou, Hebing; Gong, Yuping; Fu, Rong; Yan, Zhenyu; Huang, Wenrong; Chu, Bin; Wang, Yutong; Zhang, Yongqing |
| 2-Nov-2023 | Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF) | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 2024 | Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yin, Hewen; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 18-Dec-2024 | Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study | Zhang, Yi; Zhou, Hu; Suo, Shanshan; Zhuang, Junling; Yang, Linhua; He, Aili; Liu, Qingchi; Du, Xin; Gao, Sujun; Li, Yarong; Li, Yan; Chen, Yuqing; Wu, Wen; Zhu, Huanling; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Jing, Hongmei; Wang, Jishi; Xu, Na; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Jin, Chenghao; Li, Xin; Liu, Lin; Xu, Yajing; Wu, Dengshu; Zhang, Feng; Zhang, Jin; Wu, Liqing; Yin, Hewen; Lv, Binhua; Xiao, Zhijian; Jin, Jie |
| 15-Nov-2022 | Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score >= 2: A Prospective Multicenter Study | Bao, Li; Lu, Min-qiu; Liu, Peng; Wang, Yu-Tong; Zhuang, Junling; Zhang, Mei; Xia, Zhongjun; Li, Zhenling; Yang, Ying; Yan, Zhenyu; Jing, Hongmei; Chen, Wenming; Zhou, Hebing; Fu, Rong; Gong, Yuping; Huang, Wenrong; Zhang, Yongqing |
| 20-Apr-2023 | Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China | Zhuang, Zhe; Tian, Ying; Shi, Lei; Zou, Dongmei; Feng, Ru; Tian, Wei-wei; Yu, Hong; Dong, Fei; Liao, Aijun; Ma, Yanping; Liu, Qinhua; Liu, Shuangjiao; Jing, Hongmei; Fu, Rong; Ma, Liang-ming; Liu, Hui; Sun, Wanling; Bao, Li; Wu, Yin; Chen, Wenming; Zhuang, Junling |
| 22-Nov-2024 | Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes | Hu, Qi; Liu, Yang; Yue, Qiuyu; Zhou, Shuo; Jin, Xianghong; Lin, Fan; Huang, Xiao-Jun; Zhuang, Junling; Lu, Jin; Gao, Xiaofei; Lee, Hsiang-Ying |
| Feb-2022 | Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections | Wu, Depei; Mi, Yingchang; Weng, Jianyu; Zhuang, Junling; Ke, Xiaoyan; Wang, Chun; Liu, Kaiyan; Martinho, Monika; Winchell, Gregory A.; Zang, Yanqiao; Xu, Lianzhe |
| 5-Nov-2024 | Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications | Zhang, Yi; Zhou, Hu; Suo, Shanshan; Zhuang, Junling; Yang, Linhua; He, Aili; Liu, Qingchi; Du, Xin; Gao, Sujun; Li, Yarong; Li, Yan; Chen, Yuqing; Wu, Wen; Zhu, Huanling; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Jing, Hongmei; Wang, Jishi; Xu, Na; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Jin, Chenghao; Li, Xin; Liu, Lin; Xu, Yajing; Wu, Dengshu; Zhang, Feng; Zhang, Jin; Xiao, Zhijian; Jin, Jie |
| 1-Jun-2023 | A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF). | Zhang, Yi; Zhou, Hu; Zhuang, Junling; He, Aili; Li, Yarong; Yang, Linhua; Du, Xin; Gao, Sujun; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Sun, Kai; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Xiao, Zhi-Jian; Jin, Jie |
| May-2020 | Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia | Chen, Miao; Zhuang, Junling; Yang, Chen; Zhang, Lu; Wang, Wei; Cai, Huacong; Yu, Yanfang; Li, Jian; Zhou, Daobin; Han, Bing |
| Oct-2022 | Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie |
| 23-Nov-2021 | Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients | Chen, Miao; Bao, Li; Chen, Wenming; Fu, Rong; Guo, Rong; Jing, Hongmei; Liu, Hui; Liu, Qinhua; Ma, Yanping; Sun, Xiuli; Wang, Wei; Wang, Yafei; Yan, Xiaojing; Qian, Jiang; Zhuang, Junling |
| 15-Nov-2022 | Validation of the Impede VTE Score for Prediction of Venous Thromboembolism in Chinese Patients with Multiple Myeloma: A Retrospective Cohort Study | Bao, Li; Wang, Yu-Tong; Lu, Min-qiu; Zhuang, Junling; Chu, Bin; Shi, Lei; Gao, Shan; Fang, Li-juan; Xiang, Qiu-qing; Liu, Xi; Ding, Yue-hua; Sun, Kai |
